Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
Intravenous omadacycline followed by oral step-down administration in healthy adults achieved high faecal concentrations while preserving key bacterial species and bile acid homeostasis in the gut. These findings support Phase 2 studies directed towards the development of omadacycline as a CDI-targeted antibiotic.
Authors
- Sigmund J. Haidacher (ORCID: https://orcid.org/0000-0002-6103-1906)
- John Williamson (ORCID: https://orcid.org/0000-0002-3840-7143)
- Mohammad Jahangir Alam (ORCID: https://orcid.org/0000-0003-3412-9438)
- Chenlin Hu (ORCID: https://orcid.org/0000-0002-0444-2127)
- Eugénie Bassères (ORCID: https://orcid.org/0000-0001-8569-3931)
- Thomas D. Horvath (ORCID: https://orcid.org/0000-0001-9761-3484)
- Travis J Carlson (ORCID: https://orcid.org/0000-0001-9564-3030)
- Kevin W. Garey (ORCID: https://orcid.org/0000-0003-2063-7503)
- Jinhee Jo (ORCID: https://orcid.org/0000-0002-4772-188X)
- Khurshida Begum (ORCID: https://orcid.org/0000-0003-2039-1531)
- Yolanda T Belin
Institutions
- Austin College (US)
- The University of Texas at San Antonio Health Science Center (US)
- Baylor College of Medicine (US)
- American Pharmacists Association (US)
- Texas Children's Hospital (US)
- University of Houston (US)
- Wake Forest University (US)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1093/jac/dkaf278
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Seres Therapeutics
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases